Medical Condition News

RSS

Scientists find MODS technique most accurate for testing tuberculosis in children

An international team of researchers comparing recently-developed methods for diagnosing tuberculosis in children in resource-poor countries has concluded that the best test for high-risk children is the microscopic-observation drug-susceptibility (MODS) technique using two gastric aspirate specimens from each child tested. MODS detects the presence of bacteria causing tuberculosis using microscopes to detect typical growth patterns in culture broth.

27 Jul 2010

Lack of dental insurance a problem for millions

The Philadelphia Inquirer: Lack of dental insurance is an "endemic problem" that affects millions of people, largely those without jobs, health coverage or solid incomes. "It began with a toothache. Tori Pence, 23, could feel the hole that had suddenly developed on her tooth, and she couldn't stand either hot or cold food.

27 Jul 2010

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.

27 Jul 2010

Consumers struggle to sort out many stem cell claims

NPR reports on the confusion among consumers about stem cell therapy. It's easy to find on websites and other advertisements claims of cures for practically every medical condition, but traditional American medical doctors say that so far stem cell therapy has been proven to work in only a few blood disorders.

27 Jul 2010

Scientists develop obesity drug without neurological side effects

The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.

27 Jul 2010

Epilepsy drugs analyzed for causing increased risk of suicide in patients

While the Food and Drug Administration requires a warning of an increased risk of suicide for all epilepsy drugs, a new study shows that only certain drugs may increase the risk. The study is published in the July 27, 2010, issue of Neurology, the medical journal of the American Academy of Neurology. Newer drugs with a higher risk of causing depression than other epilepsy drugs, such as levetiracetam, topiramate and vigabatrin, were found to increase the risk of self-harm or suicidal behavior among people with epilepsy.

27 Jul 2010

QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy

QRxPharmareported today positive outcomes of its European Scientific Advice meetings on the development and registration of MoxDuo IR, an immediate release Dual-Opioid™ pain therapy. The Company is currently completing pivotal Phase 3 trials required for filing a New Drug Application (NDA) for MoxDuo IR with the United States Food and Drug Administration (FDA).

26 Jul 2010

Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability -- a core symptom of fragile X syndrome.

26 Jul 2010

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.

26 Jul 2010

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

26 Jul 2010

Brainlab launches ExacTrac Infrared Monitoring device for patient positioning during radiation therapy

Brainlab announced the availability of ExacTrac® Infrared Monitoring, an add-on device to existing treatment machines for monitoring patient positioning during radiation therapy treatments, at the American Association of Physicists in Medicine (AAPM) Annual Meeting last week.

26 Jul 2010

Obesity linked to early puberty in girls

A review of more than 100 studies found overweight girls tend to reach puberty earlier than their peers do.

26 Jul 2010

Calibra Medical's Finesse insulin patch-pen receives FDA clearance for use with Novo Nordisk's Novolog

Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk's Novolog® rapid acting insulin. Combining the mealtime therapy-adherence benefits of insulin pumps with the simplicity and affordability of syringes and pens, Calibra's novel bolus-only patch-pen is a small, adhesively attached, flat device that can be operated discretely through clothing to deliver mealtime, snack time, and correction bolus insulin in seconds.

26 Jul 2010

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus standard-of-care.

26 Jul 2010

Boston Scientific launches Neuroform EZ Stent System

Boston Scientific Corporation today announced the U.S. and European launches of the Neuroform EZ™ Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. The Company plans to launch the product immediately in both markets.

26 Jul 2010

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc.. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a humanized antibody to hepatocyte growth factor (HGF).

26 Jul 2010

Researchers discover potential method for neurodegenerative disease detection

New investigations, initiated by research workers at CIC bioGUNE and led by Dr. Aitor Hierro, have opened possibilities for making progress in the knowledge and prediction of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), according to the journal of The Proceedings of the National Academy of Sciences of the United States of America.This study opens the possibility of research in humans to detect this pathology before the symptoms arise.

26 Jul 2010

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

26 Jul 2010

Medtronic glucose monitoring device helps owners manage pets’ diabetes

The treatment of diabetes was revolutionized in 1922 when insulin was isolated from dogs. Since then, significant advances in human medicine have made diabetes more manageable for patients. Now, human medicine has returned the favor and used these advances to help dogs with diabetes. A University of Missouri researcher is using a continuous glucose monitoring device - commonly used in humans with diabetes - to help treat dogs and other animals. The device, which provides a detailed glucose picture of an animal over several days, will help pet owners manage their pets' diabetes.

26 Jul 2010

Report on shaping marketplace to support successful oncology product launches

The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new oncology products are scrutinizing their strategies and tactics to support market education.

26 Jul 2010

Medical Condition News

Scientists find MODS technique most accurate for testing tuberculosis in children

Lack of dental insurance a problem for millions

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Consumers struggle to sort out many stem cell claims

Scientists develop obesity drug without neurological side effects

Epilepsy drugs analyzed for causing increased risk of suicide in patients

QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy

Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Brainlab launches ExacTrac Infrared Monitoring device for patient positioning during radiation therapy

Obesity linked to early puberty in girls

Calibra Medical's Finesse insulin patch-pen receives FDA clearance for use with Novo Nordisk's Novolog

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

Boston Scientific launches Neuroform EZ Stent System

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

Researchers discover potential method for neurodegenerative disease detection

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Medtronic glucose monitoring device helps owners manage pets’ diabetes

Report on shaping marketplace to support successful oncology product launches

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News